The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...

The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

Poor treatment of asthma and COPD puts a huge burden on the NHS. For example, £1 billion is spent on asthma treatment in the UK each year and represents 60,000 to 65,000 hospital admissions. In ...

Patients with COPD had better inhaler adherence when invited to enroll in a program that lowers cost sharing for maintenance inhalers and offers medication management services, according to results ...

Whether treating COPD or asthma, Trelegy Ellipta may help ease symptoms over time. The medication is not FDA approved as a rescue inhaler to relieve sudden breathing difficulties. A doctor can ...

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

Recent research published in The Lancet Respiratory Medicine confirms that emphysema was detected in 24% to 31% of patients undergoing lung cancer screening. This means that for millions of Americans, ...

Medicare usually covers the cost of inhalers for people with asthma, COPD, or certain other conditions under Part D or Medicare Advantage (Part C) plans. With Medicare coverage, you may still have ...

Many Part D prescription drug plans cover Trelegy Ellipta, but costs can vary by plan type and insurer. Read more.